Novo Nordisk's pricing strategies during the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of value gouging, declaring the stark distinction concerning U.S. selling prices and people in Europe and copyright. But Rybelsus and copyright do